FDA Stem Cell Initiative Emphasizes Interaction With Industry, Outside Scientists
This article was originally published in The Pink Sheet Daily
Executive Summary
Exchange of information will facilitate product development in line with regulatory requirements, FDA says.
You may also be interested in...
FDA Outlines Priorities For Next Five Years In Strategic Report
The agency identifies four overarching priorities: advancing regulatory science and innovation; strengthening the global supply chain; strengthening compliance and enforcement activities; and addressing unmet public health needs.
FDA Regulatory Science Infrastructure Gets $25 Million Push In Budget
Gaining the expertise and infrastructure needed to assess products of the future - such as biosimilars and those based on stem cells and nanotechnology - is the goal of a $25 million scientific modernization effort proposed in the fiscal 2011 FDA budget
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.